The invention relates to new deuterated morphine derivatives of general formula (I), and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixtures of enantiomers or combinations thereof, as well as polymorphs, tautomers, solvates, salts, esters and prodrugs thereof, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them.
The solution according to the present invention relates to nanocomposites, which are useful for the controlled delivery of active ingredients into the central nervous system.
The invention relates to the use of pharmaceutical compositions containing as the active agent a compound of formula I in the treatment of dermal wounds.
The invention relates to a continuous flow chemical method for the solid phase synthesis of peptides and enantiomers, diastereomers, stereoisomers, mixtures, salts and/or derivatives thereof.
The invention relates to peptides and peptidomimetics useful for reducing the neurotoxicity of amyloid peptide aggregates or prion-like (prionoid) protein aggregates, the invention further relates to pharmaceutical compositions containing said peptides and/or peptidomimetics, to the use of said peptides and/or peptidomimetics in the manufacture of medicines useful for the prophylaxis or treatment of diseases that can be cured by protection against the detrimental effect of Αβ-peptides /abnormal Αβ aggregation leading to amyloid plaque formation, and it relates to the use of said peptides and/or peptidomimetics in the prophylaxis or treatment of the above mentioned diseases.
Danubia Wins First Place of the Companies For The Future Award 2024
TRADEMARK PROTECTION OF A COLOUR AGAINST THE SHADE OF THE SAME COLOUR ‘MILKA’
REIMBURSEMENT OF ENRICHMENT ACHIEVED BY TRADEMARK INFRINGEMENT
Measuring and reflecting the utilization of research results in university rankings
NOTICE OF TERMINATION FOR A LICENSE AGREEMENT